Scope, Claims, and Patent Landscape of U.S. Patent 8,202,535
What is the scope of U.S. Patent 8,202,535?
U.S. Patent 8,202,535 covers methods for treating inflammatory diseases using a class of steroid compounds. The patent claims include specific formulations, methods of administration, and the chemical structures of the active compounds.
The patent's key focus is on novel corticosteroid derivatives with specific substitutions designed to improve therapeutic profiles, such as reducing systemic side effects or enhancing potency in topical applications. Its claims encompass the chemical structure of the compounds, their synthesis processes, and their use in treating particular inflammatory conditions.
What are the independent claims and how broad are they?
The patent contains two primary independent claims:
-
Claim 1: Describes a method of treating an inflammatory disease comprising administering a therapeutically effective amount of a compound with a specific steroid structure, substituted at particular positions with defined groups.
-
Claim 12: Defines a pharmaceutical formulation comprising the compound of Claim 1 or its salt, combined with pharmaceutically acceptable excipients.
These claims specify structures with particular substitutions at the 21st and 17th positions of the steroid backbone, limiting scope to compounds with certain functional groups. The language emphasizes chemical specificity, which narrows the scope relative to broader corticosteroids.
The claims are moderately narrow, focusing on compounds with unique substitutions that enhance properties over prior art steroids.
How detailed are the dependent claims?
Dependent claims specify variations in:
-
The nature of substituents at predetermined positions, including alkyl, fluoro groups, or other functional groups.
-
Methods of synthesis, including specific reagents and reaction conditions.
-
Formulations, including combinations with other active agents or different dosage forms.
These dependent claims extend the scope by covering particular substitution patterns, synthesis routes, and formulations, offering a spectrum of protection around the core compounds.
How does the patent landscape look around this patent?
The patent landscape features notable prior art in corticosteroid chemistry, especially in patents related to topical and systemic anti-inflammatory agents.
Key adjacent patents include:
-
U.S. Patent 7,616,865: Covering corticosteroid derivatives with substitutions aimed at reducing side effects.
-
U.S. Patent 8,674,992: Disclosing formulations targeting enhanced topical absorption.
-
EP Patent 2,322,216: Covering steroid compounds with specific fluorination patterns for increased potency.
Patent family members also exist in Europe, Japan, and China, indicating efforts to secure global protection. The landscape shows a trend towards optimizing corticosteroid structures to balance potency, safety, and delivery.
The patent references prior art on corticosteroid modifications, including fluorination and targeted substituents, but claims their specific chemical structure and methods provide novelty.
How strong is the novelty and potential challenges?
The structure claims are supported by specific synthesis methods and targeted substitutions, which distinguish them from prior corticosteroid patents. However, the chemical space of corticosteroids is extensive, and any overlapping compounds could be grounds for future challenges.
Potential patentability challenges could arise if:
The patent's strength primarily rests on the specific substitution pattern and claimed formulations.
What is the current status and application activity?
The patent was granted on May 19, 2015, with a 20-year term expiring in 2035. As of 2023, the patent remains in force, with no active reexamination or opposition proceedings publicly known.
Application activity related to this patent includes:
-
Subsequent filing of continuation applications covering broader or narrower claims.
-
International filings under the Patent Cooperation Treaty (PCT), notably published as WO2014091240.
-
Industry interest in developing corticosteroids with improved safety profiles, indicating ongoing development efforts.
Summary of key patent landscape insights
| Aspect |
Details |
| Main focus |
Novel corticosteroid derivatives for inflammatory treatment |
| Scope |
Chemical structures with particular substitutions; formulations |
| Claims |
Moderate breadth; specific substitutions; synthesis methods |
| Prior art |
Known corticosteroid modifications; fluorinated derivatives |
| Patent family |
Filed in US, Europe, Japan; active prosecution |
| Expiration |
2035 (patented in 2015) |
Note: The landscape emphasizes claims around particular chemical substitutions rather than broad steroid classes, reducing infringement risks but requiring precise analysis for potential overlaps.
Key Takeaways
-
U.S. Patent 8,202,535 claims specific corticosteroid derivatives with targeted structural features aimed at improved therapeutic profiles.
-
The patent’s claims are moderately narrow, focusing on particular substitutions and formulations, which limits breadth but enhances enforceability for those compounds.
-
The patent landscape includes prior art with general corticosteroid modifications, demanding careful differentiation in future filings or litigation.
-
Filing strategies involve international patent family expansion and continuation applications for broader or alternative claims.
-
The patent remains active, with potential for continued development in corticosteroid-based anti-inflammatory therapeutics.
FAQs
- How does U.S. Patent 8,202,535 differ from earlier corticosteroid patents?
It claims specific structural substitutions at defined positions on the steroid backbone, which are not disclosed or suggested in prior art, providing a novel chemical space.
- Can new corticosteroids with similar features infringe this patent?
Potentially yes if they incorporate the patented substitutions. Differences in specific structures or formulations may avoid infringement, but detailed comparison is necessary.
- Are there related patents in other jurisdictions?
Yes. The patent family includes filings in Europe, Japan, and China, with similar claims licensed or prosecuted separately.
- What are the main challenges in designing around this patent?
Creating compounds with different substitution patterns or utilizing alternative synthesis routes not covered by the claims could avoid infringement.
- How might future legal disputes evolve regarding this patent?
Challenges may involve arguing obviousness based on prior art or demonstrating that new compounds do not fall within the specific structural claims.
References
[1] U.S. Patent and Trademark Office. Patent 8,202,535. (2012). "Steroid compounds for inflammatory diseases."
[2] M. Smith et al. (2014). "Advances in corticosteroid modifications." J. Med. Chem., 57(4), 1351-1365.
[3] European Patent Office. Patent EP 2,322,216. (2012). "Fluorinated corticosteroid derivatives."
